ArticleCellular and molecular gastroenterology and hepatology2026
Dietary Oxalate and Intestinal Inflammation: Evidence From Experimental Colitis and Inflammatory Bowel Disease Patient Cohorts.
Article in Cellular and molecular gastroenterology and hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors.
Funding
Abstract
BACKGROUND &
aimsThe role of diet in the pathogenesis of inflammatory bowel diseases remains unclear. Most dietary interventions for inflammatory bowel disease improve symptoms without consistent mucosal healing; exceptions include exclusive enteral nutrition and exclusion diets in patients with Crohn's disease. Oxalate, a naturally occurring compound found in all plant foods, is absorbed through the gut and has been shown to activate systemic and renal proinflammatory immune responses. However, the impact of intestinal oxalate on innate immune response in the context of inflammatory bowel disease is unknown.
methodsWe measured gene expression, stool oxalate content, and dietary intake in people with inflammatory bowel diseases and controls. Complementary studies were conducted in mouse models of chemically induced colitis, spontaneous colitis, and ex vivo cell culture systems to evaluate the relationships observed between oxalate transporter expression, stool oxalate content, and mucosal inflammation.
resultsIntestinal oxalate transporters, SLC26A2 and SLC26A3 are consistently downregulated across inflammatory bowel disease subtypes (Crohn's disease, ulcerative colitis), inflammatory bowel disease tissues (colon, ileum), and in mouse models of experimental colitis irrespective to experimental diet assignment. In patients with Crohn's disease, we observed higher stool oxalate content despite variable dietary oxalate intake. Altered expression of SLC26A6 corresponded to stricturing behavior of disease in patients with Crohn's disease. Altered expression corresponded more directly to higher stool oxalate content and increased disease activity in mice fed an oxalate supplemented diet.
conclusionsDietary oxalate may exacerbate innate immune responses in susceptible individuals. Expression of oxalate transporters may be a disease-associated biological signal of both sensitivity to dietary oxalate and possibly, pathogenesis and clinical trajectory of patients with inflammatory bowel disease. This warrants future exploration of the role of dietary oxalate in mucosal inflammation in inflammatory bowel diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.